Advanced Accelerator Application SA(ADR) Stock

Equities

End-of-day quote Nasdaq Other stock markets
-	-

2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE
2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE

Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	17-11-03	RE
Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	17-10-30	RE
Advanced Accelerator Application : Novartis to buy France's Advanced Accelerator for $3.9 billion	17-10-30	RE

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications	18-12-03	GL
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer	18-02-12	GL
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer	18-02-01	GL
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors	18-01-26	GL
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer	18-01-22	GL

Novartis : Le conseil d'administration d'AAA recommande l'offre de 3,9 mds de dollars de Novartis	17-12-06
Advanced Accelerator Application : Novartis offre 3,9 milliards de dollars pour le français Advanced Accelerator	17-10-30
WDH/Novartis will US-Unternehmen Advanced Accelerator Applications übernehmen	17-10-30
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	17-10-30
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	17-10-30

Managers	Title	Age	Since
Caio Kugelmas DFI	Director of Finance/CFO	-	-
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	19-09-30
Ute Simon CTO	Chief Tech/Sci/R&D Officer	-	20-03-31

Members of the board	Title	Age	Since
Frédéric Collet BRD	Director/Board Member	-	17-12-31
Jessica Toepfer BRD	Director/Board Member	-	17-12-31
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	19-09-30

Sector

	1st Jan change	Capi.
KYOWA KIRIN CO. LTD.	+10.23%	8.96B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.19B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.58%	4.77B
YUHAN CORPORATION	+12.50%	4.26B
BETTA PHARMACEUTICALS CO., LTD.	-20.70%	2.37B
INDIVIOR PLC	+12.83%	2.3B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.65%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.17B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B